Even accounting for recent losses, the tech-heavy NASDAQ index is up 28% so far this year, leading the way in an overall bullish market. The surge in the NASDAQ has been fueled by investors gravitating towards tech giants. According to Chris Harvey, head of equity strategy for Wells Fargo, the rally is solid, and it will remain so until the Federal Reserve cranks up interest rates enough to kill it. Harvey notes that inflation, while falling, remains persistently above the central bank’s 2% targ
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) 16.04.2023 / 21:01 CET/CESTThe issuer is solely responsible for the content of this.
According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.
EQS-News: MorphoSys AG / Key word: Miscellaneous
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL. | April 16, 2023
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary